offered to all patients in the United Kingdom with a bleeding disorder for which the genetic basis is known. Even in those disorders that are suspected to be inherited but for which the genes responsible
have not yet been identified, testing has been offered through gene discovery programs such as Genomics England's 100 000 Genomes Project. In the future, the expectation will be that selected individuals suspected to have a bleeding or platelet disorder not amenable to standard coagulation and genetic profiling will undergo large NGS panel or exome-based sequencing as part of their investigation.
For haemostasis genes with a well-established link between the gene involved and the clinical presentation (the genotype-phenotype relationship), the reporting and clinical interpretation of variants is relatively straightforward. 1 However, for many of the genes assayed by NGS, the phenotypic consequences of genetic variants have been studied in relatively small numbers of pedigrees, and so prediction of the clinical effects of a variant is more difficult. This creates challenges for those reporting the variants and for the clinicians explaining the results to patients. There has been extensive work that has generated tools and guidance for the laboratory reporting of variants [2] [3] [4] but there has been relatively little guidance for clinicians.
| TERMINOLOGY
Previously, the terms "mutation" and "polymorphism" have been used to distinguish variants based upon the rarity or commonness of the variant in the general population (allele frequency) and whether they are considered to be disease-causing or not. However, there are many variants with variable phenotypic effects and allele frequencies in different populations and so these terms that were designed to be mutually exclusive are often not. This leads to confusion when both terms are used to describe the same variant and so this distinction should no longer be used in the clinic. Even for variants that seem to clearly fall into one of these categories, patients may draw more negative inferences with "mutation" while "polymorphism" may be inaccurately perceived to be more benign. 8 Neutral terms, such as "variant," without this ambiguity should be used when describing sequence differences. 2, 9 In order to reduce ambiguity when referring to the exact location of a variant, the Human Genome Variation Society (HGVS) produced guidance on the nomenclature to be used, 9 with any subsequent nomenclature updates issued and explained on the HGVS website (https://varnomen.hgvs.org/). The numbering of genetic or protein sequences is now uniform, but many historical references use different numbering for coagulation genes and proteins using the conventions that were in place at the time. This can lead to misidentification of a variant when referring to the published literature or misdiagnosis when a patient's result is compared with a historical report from a relative. To reduce these risks, specialist coagulation laboratories that also provide genetic testing should report using the HGVS nomenclature and version number alongside previous (legacy) numbering systems. As genetic testing becomes increasingly centralized, the knowledge of legacy numbering systems is gradually lost and so clinicians need to be aware of this potential pitfall when • Variant has some characteristics of being diseasecausing, but there is conflicting evidence indicating that it may be benign (eg, unexpectedly high frequency in the normal population) OR • There is simply insufficient evidence to place in one of the other categories • Probability of being pathogenic, 0.1 < P < 0.9
TA B L E 1 Variant classification according to American College of Medical Genetics and Genomics guidelines
• Should not be used in clinical decision making • In disorders with informative phenotype assays, discuss with the reporting laboratory whether cosegregation studies might enable reclassification into class 4 or 2. It should be made clear that testing of relatives in this situation is not the same as screening for the disease • The accumulation of more data over time might lead to reclassification and so the result should be reviewed periodically.
2-likely benign
• Variant found more commonly in the general population than expected for the known frequency of the disorder • Probability of being pathogenic, 0.001 < P < 0.1
• Normally not reported as no clinical consequences
1-benign
• The variant does not segregate with the disease (in families with two or more affected individuals) • Functional studies demonstrate no significant effect • Probability of being pathogenic, P < 0.001
• Normally not reported as no clinical consequences Probability of variant being pathogenic from Tavtigian et al. 10 comparing new reports with the published literature or previous reports on other pedigree members.
The American College of Medical Genetics and Genomics (ACMG)
published guidelines in 2015 setting out how to standardize the classification and reporting of sequence variants. 2 They published a fivetier classification system ( Table 1) that is now the standard used in the United Kingdom and globally. 4 It is essential that clinicians undertaking genetic analysis have an understanding of this classification and how to convey the information in reports using it to the patient and family members. The probability of a variant in a specific class being pathogenic should be borne in mind when using a result to influence clinical management. Of note, the probability of a class 4 "likely pathogenic" variant actually being pathogenic is 0.9 < P < 0.99.
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Recommendations:
1. Neutral terms such as "variant," "change" or "alteration" should be used instead of "mutation" or "polymorphism" when describing differences between a patient's sequence and the reference sequence.
Clinical records should describe a variant using Human Genome
Variation Society (HGVS) nomenclature and numbering. If helpful for the understanding of the phenotypic effect, legacy numbering should also be included alongside the HGVS numbering. 
| DE ALING WITH UN CERTAINT Y
Once the results of genetic testing are available, it may be apparent that there is a definite genetic variant which fully explains the phenotype and any family history. This would be designated "pathogenic" or class 5 in the classification given above. However, it is not infrequent that some uncertainty remains. This may be because a "likely pathogenic variant" or "variant of uncertain significance" has been identified, or because no potentially causative variant has been identified. These situations may arise from a number of factors described below. Because of the potential for misinterpretation, it is recommended that results are always reported to appropriately trained clinicians. Note that variants of uncertain significance may be re-categorized over time and will require regular review as more evidence of their status becomes available.
| Limitations of the techniques used
Until recently, genetic analysis relied on the identification of a candidate gene, or genes, which were then analysed by Sanger sequencing following PCR amplification of the coding sections of the gene. 
| Mosaicism, lyonization and chromosomal anomalies
For simplicity, genetic testing is invariably performed on peripheral blood samples. This is often not the tissue affected by the disorder and may also not be representative of all the patient's germ cells which produce sperm or ova. Disparities between these may arise from somatic mosaicism, where a new DNA variant is present in only a proportion of cells in a patient, having arisen after they started to form as a very early embryo. Again, the advent of NGS has improved our ability to detect small populations of variant-carrying cells in minor degrees of mosaicism. 11 In practice, it may be difficult to distinguish mosaicism affecting a proportion of cells in a parent, from a de novo variant which affects a single sperm or egg, particularly because the mosaicism may be limited to the gonads (germinal mosaicism). Nevertheless, this distinction is important because the implications for other offspring are quite different.
In a Swedish study of 45 "sporadic" cases of haemophilia, 17
were found not to be present in the mother. Five of these cases were analysed in more detail, and 1/5 found to be a mosaic with 7% of peripheral blood cells carrying the variant. 12 Leuer et al 13 found mosaicism in 13% (confidence interval 0.2%-25%) of 61 families with sporadic haemophilia due to single nucleotide variations. The possibility of mosaicism in a parent of an apparent de novo case of an X-linked or dominantly inherited condition can never be excluded, and the parents of a child with an apparent de novo variant should be made aware that their other children could inherit the same condition even if their own genetic testing is negative.
For variant identification in a female, the phenomenon of X chromosome inactivation should not cause problems. However, this can confound phenotype predictions in females with X-linked conditions, such as factor VIII or IX levels, and whether or not a carrier will be affected by bleeding symptoms. Extreme lyonization with inactivation of the unaffected X chromosome will result in a more severe phenotype in a carrier female than expected. [14] [15] [16] This results in a similar effect to that seen if a variant on one X chromosome is present in a female who has a chromosomal anomaly which is affecting what would otherwise be the normal allele. In females where the phenotype is different from that predicted, karyotype analysis may be informative.
| Variants of uncertain significance
In a significant proportion of variants, it is not possible to say with certainty whether they are benign or pathogenic. These class 3 "variants of uncertain significance" (VUS) represent 18% of reported variants in ThromboGenomics (an NGS panel of about 100 coagulation genes) and 14% in BRIDGE BPD (an NGS whole-genome study, personal communication from Dr Kate Downes, Cambridge). This percentage will undoubtedly rise as analysis is increasingly applied to haemostatic genes in which the effects of variation have not been well studied. Uncertainty in this context does not exclude the possibility of a causal or pathogenic state, but pathogenicity cannot be confirmed or excluded due to lack of evidence. The probability of a VUS being pathogenic ranges from 0.1 < P < 0.9. 10 Clinicians should note that VUS can be upgraded to pathogenic or downgraded to benign as more data become available and so a variant's classification should be periodically reviewed. Because this will have to be con- 3. Conservation of the residue across species. Variants of poorly conserved residues are less likely to be pathogenic.
4. In silico prediction algorithms. These may indicate the impact of a missense or potential splice variant but it should be noted that the predictions are based upon generalized variant effects on, for example, protein structure. These should not be relied on alone to assign pathogenicity but, in combination with knowledge of the key structural features that alter function of a particular protein or how expression of a particular gene is regulated, they can provide additional evidence.
5. Functional studies may provide demonstrable evidence of pathogenic effect.
These strategies are mostly applicable to coding variants and the classification of non-coding variants in deep intronic and distant regulatory regions is particularly challenging. These variants may not appear in control data sets, as the regions are still relatively inaccessible even with NGS, and so the minor allele frequency may not be known.
Ongoing research into the epigenome, coupled with bioinformatic tools aimed at predicting the effects of distant regulatory elements, may assist in classification of these variants in the future. For the moment clinicians should await further data on these variants accumulated through large-scale, collaborative research.
Recommendations:
1. Exercise caution when dealing with apparent "de novo" variants and inform parents that there is still a small chance of other affected children due to the possibility of mosaicism.
When dealing with a reported Variant of Uncertain Significance (VUS)
a Do not rely on the VUS to direct clinical management.
b In disorders with informative phenotype assays, discuss with the reporting laboratory whether cosegregation studies might enable reclassification into class 4 or 2. It should be made clear that testing of relatives in this situation is not the same as screening for the disease for diagnostic purposes.
c Check the status of class 4 (likely pathogenic) and class 3 (VUS)
during routine clinical reviews to establish whether the variant has been reclassified. When a variant's classification changes, the reporting laboratory should issue a revised report.
| IN CIDENTAL FINDING S
Any genetic test involving many genes, particularly whole-genome analysis, will detect at least some of the 3 million differences in DNA (0.1% of DNA sequence) which exist between any two people.
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Most of these are part of normal variation and of no consequence, but some have a clear association with disease. If this is unrelated to the clinical problem being investigated, these are referred to as "incidental findings". 19 The likelihood for generating incidental findings depends on the type and clinical focus of the DNA test. Essentially, the more genes that are included in a test, the higher the chance of uncovering an incidental finding.
An incidental finding would usually be one of: 2. A finding which contradicts stated biological relationships between family members.
A finding that may challenge a person's assumed identity in relation
to a genetically mediated characteristic such as ethnicity or gender.
Case scenario examples for the different types of incidental finding are to be found in the Appendix 1 to this document ( Table 2 ).
The possibility of incidental findings arising should be discussed as part of the consent process. If a patient expressly states that they wish to avoid the possibility of incidental findings, then the feasibility of testing using a more limited strategy, such as a single gene analysis as opposed to whole-genome sequencing, should be discussed. It should be borne in mind that sequencing platforms, such as 100 000 Genomes, may have filters applied to include or exclude specific genes or variants from analysis although this cannot be tailored to individual cases. Whether or not to report an incidental finding should depend on the predicted clinical effect and how strong the evidence is for potential pathogenicity. 19 In practice, this depends on whether it is an "actionable" finding for potential patient benefit which is dependent on how severe the associated phenotype 
| CORREL ATING G ENOT YPE AND PHENOT YPE IN THE CLINI C
When conveying information about a genetic report in a patient- being able to discuss the probability of carriership with a patient is helpful in managing expectations. 23 In these circumstances, if it is possible to determine that the predicted risk of a particular female relative being a carrier is very low, then genetic screening without an identified variant is of little or no benefit. This is because a negative result (the most likely outcome) will not exclude carrier status, and assigning pathogenicity for any variants identified will be difficult because an association has not been established with the phenotype in the pedigree.
In the example pedigree shown in Figure 1 The maternal carriership rate is affected by the relative mutation rates in male and female gametes and is in keeping with the knowledge that variants causing severe haemophilia mostly arise during spermatogenesis, and mainly in the unaffected maternal grandfather (I.2), or in an earlier unaffected male ancestor of the grand-maternal line. However, the figures above derive from observation across many families and therefore only represent the figure for an "averaged" family structure in relation to the number of unaffected male sibs in each generation. In practice, each family structure is individual, and the carrier risk of the maternal grandmother will be considerably higher (approaching half of the mother's risk) where there is no unaffected male sib in the mother's or grandmother's generation.
A maternal aunt (II.3) would be predicted to have half the risk of her mother, that is, 1%-6% for an "averaged" family, but up to 15%-20%
(up to 1/4 of her sister's risk) if neither she nor their mother have any unaffected brothers, and she has no sons herself. Where the aunt has a low probability of carriership, genetic screening for an unknown variant is of very limited value and simply advising the consultand of her probability is likely to be more useful. Where the risk is higher (eg, 15%-20%), a combination of factor level and DNA analysis should be considered.
Evaluating the correlation between genotype and phenotype is key, especially for variants classified as types 3 or 4.
Close collaboration between the laboratory scientists who will 
Recommendations:
1. Clinicians requesting genetic analysis should enter on the request form all the laboratory and clinical data that might be used in disease classification.
A detailed pedigree showing the laboratory and clinical pheno-
type of family members should be obtained when the test is requested.
| CON S ENT
Written, informed consent is recommended prior to testing individuals for heritable bleeding conditions 7 and should be taken only after comprehensive, non-directive genetic counselling. There is guidance in the UK on how consent should be sought for genetic testing within clinical practice. 30 However, these predate the routine use of high-throughput gene testing methods and updated guidance is in development.
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In principle, counselling and subsequent consent for genetic testing should cover several areas. These are set out in Table 3 give their own informed consent would not normally be acceptable.
An example of this would be to inform carrier status for haemophilia in an asymptomatic preadolescent girl. Children may not remember having the test and the authors recommend, in particular bearing in mind the increasing complexities of genetic testing, that when children transition to adulthood re-consenting should be considered.
Finally, it is important to make sure that the potential to share the data is discussed. Not only is genetic information of significance to family members, but also large numbers of patients providing linked genotype-phenotype data becomes a powerful tool for developing understanding of pathogenesis of disease and future treatments at a research level, particularly for rare diseases.
1. Consent should be taken prior to genetic testing for all inherited bleeding disorders and should cover: breadth of testing, implications of results for patient and extended family, VUS and incidental findings, data sharing and non-haemostatic effects of some variants.
2. If genetic testing is carried out on a child with parental consent, the child should be re-consented when he/she reaches adulthood and/or has capacity.
DISCL AIMER
While the advice and information in this guidance are believed to be true and accurate at the time of going to press, neither the authors, the UKHCDO nor the publishers accept any legal responsibility for the content of this guidance.
ME THODOLOGY
This Good Practice Paper was written by the Genetics Working Party of the UKHCDO according to the British Society for Haematology (BSH) process set out at https://b-s-h.org.uk/. The UKHCDO produces Good Practice Papers to guide health care professionals in areas where there is a limited evidence base but for which a degree of consensus or uniformity is likely to be beneficial to patient care. reporting using the Boolean operator AND with bleeding disorders.
LITER ATURE RE VIE W DE TAIL S
This generated 31 results which were analysed in full. A further search was done using genetic interpretation filtered with guideline and English language. This generated 45 results of which seven were considered relevant. Publications not identified by these searches but within the personal knowledge of the working party and considered to be relevant were also included. 
RE VIE W OF THE MAN USCRIP T

CO N FLI C T O F I NTE R E S T
The UKHCDO paid the expenses incurred during the writing of this 
C A S E 2
A 17-year-old schoolgirl studying biology A-level understands that she must be a carrier for haemophilia B as this affects her father, 
C A S E 3
The variant in a 23-year-old man with haemophilia A is found to be a translocation between the X chromosome (through the F8 gene) and an autosome, conferring unexpected additional fertility or reproductive implications.
Do inform and refer for genetic counselling.
C A S E 4
A 12-gene coagulation factors panel test is used to investigate a 38-year-old Irish-American man with possible von Willebrand disease.
The result finds not only a pathogenic VWF gene variant, but also a variant in the FGA gene (coding for the fibrinogen α chain), which has been reported in two families of similar ethnicity, and does not affect clotting but predicts a high likelihood for him to develop nephrotic syndrome due to renal amyloidosis.
The small possibility of revealing additional unexpected health information should be raised when taking consent. Review evidence for variant pathogenicity and predictive value of this information. Do inform,
and consider involvement of other specialists eg Clinical Geneticist.
C A S E 5
A 31-year-old woman with a suspected platelet function disorder, but no likely causative variant on a 6-gene panel test, undergoes whole-exome sequencing. In addition to finding a likely pathogenic variant and a VUS in two different genes associated with platelet function, she proves coincidentally to be heterozygous for the factor V Leiden variant. The current approach involves PCR amplification of the target sequence to create a template which is then subjected to stepwise incorporation of terminating dideoxynucleotides which are labelled with discrete fluorescent dyes. This allows the DNA sequence to be read using an automated analyser.
Southern blot-A technique developed by Edwin Southern in 1975.
The initial step is cutting of the target DNA by restriction endonucleases. The restriction fragments are then separated by electrophoresis, transferred or "blotted" onto a membrane and detected by probes labelled with either a radioactive or a non-radioactive reporter system. Fragment size is altered by gross genetic defects such as inversions or deletions.
